Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) announced multiple preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE